Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial

Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial

Introduction Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary condition that causes the formation of cysts primarily in the kidneys. The continuous growth of multiple cysts leads to the destruction of functional parenchyma, which may progress to end-stage kidney disease. Tolvapta...

Full description

Saved in:
Bibliographic Details
Main Authors: Roland Schmitt, Sebastian Häckl, Armin Koch, Elisabeth Bahlmann-Kroll, Stefanie Kramer, Vera Christine Wulfmeyer, Julian Glandorf, Jessica Kaufeld, Dagmar Hartung, Bernhard M W Schmidt, Kai Schmidt-Ott
Format: Article
Language:English
Published: BMJ Publishing Group 2024-12-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/12/e088317.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/14/12/e088317.full

Similar Items